We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Strengthens Patent Position on Lead Program MOR103
News

MorphoSys Strengthens Patent Position on Lead Program MOR103

MorphoSys Strengthens Patent Position on Lead Program MOR103
News

MorphoSys Strengthens Patent Position on Lead Program MOR103

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Strengthens Patent Position on Lead Program MOR103"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's most advanced proprietary compound MOR103. The new patent (US 7,867,495) covers MorphoSys's HuCAL antibody against GM-CSF as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in 2026, not including any potential extensions.

This newly issued patent complements a US patent granted in 2008 covering medical uses of antibodies against GM-CSF, to which MorphoSys has exclusive access under a license agreement with the University of Melbourne. Together, the two patent families provide strong intellectual property protection for the MOR103 program.

"The protection of our intellectual property is a central part of MorphoSys's business model," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "We will continue to strengthen still further our intellectual property position in antibody-based products and services, particularly in our most important markets Europe, the USA and Asia."

Human GM-CSF (Granulocyte macrophage-colony stimulating factor), the target molecule of MorphoSys's lead program MOR103, is implicated in a number of inflammatory and other conditions including rheumatoid arthritis (RA) and multiple sclerosis (MS). The HuCAL-derived, fully human antibody is currently being tested in a clinical Phase 1b/2a trial in RA patients. Additionally, MorphoSys plans to start a Phase 1b safety study of MOR103 in multiple sclerosis patients in 2011.

Currently, the Company is prosecuting more than 40 different proprietary patent families world-wide, in addition to those being pursued in cooperation with its partners.

Advertisement